Barjaktarevic Igor, Arenberg Doug, Grimes Brandon S, Ruchalski Kathleen, Aberle Denise R
Division of Pulmonary and Critical Care Medicine, Clinical Immunology, and Allergy, David Geffen School of Medicine at UCLA, Los Angeles, California.
Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor, Michigan.
Semin Respir Crit Care Med. 2016 Oct;37(5):689-707. doi: 10.1055/s-0036-1592187. Epub 2016 Oct 12.
Each year, more than 1 million persons worldwide are found to have a lung nodule that carries a risk of being malignant. In reality, the vast majority of lung nodules are benign, whether identified by screening or incidentally. The consequences of delaying or missing the diagnosis of lung cancer can be substantial, as can be the consequences of invasive procedures on patients with benign lung nodules. The challenge for the clinician caring for these patients is to differentiate between benign and malignant nodules with the least harm possible. In this review, we will discuss management strategies of the indeterminate pulmonary nodule and will review recent advances and harm-reduction strategies.
每年，全球有超过100万人被发现有存在恶变风险的肺结节。实际上，无论通过筛查发现还是偶然发现，绝大多数肺结节都是良性的。延误或漏诊肺癌的后果可能很严重，对良性肺结节患者进行侵入性检查的后果也可能如此。照顾这些患者的临床医生面临的挑战是尽可能减少伤害地鉴别良性和恶性结节。在本综述中，我们将讨论不明确肺结节的管理策略，并回顾近期的进展和减少伤害的策略。
